Ghaith Noaiseh is a Rheumatology/Immunology physician. OpenAlex indexes 35 publications with 590 citations (h-index 10); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1000 E 101st Ter
Kansas City, MO 641313366
Telephone
913-574-2438Provider last certified this registry record 4 Jan 2024.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year202525 payments$38,568openpaymentsdata.cms.gov ↗
- ARGENX US, INC.Program year202512 payments$16,153openpaymentsdata.cms.gov ↗
- Amgen Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
30.7%TNF inhibitor8.5%Enbrel Sureclick45%Enbrel27%Humira(Cf) Pen20%Cyltezo(Cf) Pen8%Part D<11 patientsAntirheumatic Agent6.7%Leflunomide100%Part D≥42 patients+ 9 more classes in this area
Antiparasitic
25%Antimalarial25%Hydroxychloroquine Sulfate100%Part D≥141 patientsNervous system
21.3%Cholinergic Receptor Agonist12.6%Pilocarpine Hcl63%Cevimeline Hcl37%Part D≥45 patientsGabapentinoids5.6%Gabapentin51%Pregabalin49%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Nipocalimab for the treatment of moderate-to-severe Sjögren’s disease: a plain language summary of the DAHLIAS study
Expert Review of Clinical Immunology
2026 - 26-CCC-11108-ACC BIOPSY-PROVEN HYDROXYCHLOROQUINE CARDIOTOXICITY DESPITE NORMAL IMAGING: A RARE CASE REQUIRING HEART TRANSPLANTATION
Journal of the American College of Cardiology
2026
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
David Felson, MD
Boston University
Marc Hochberg, MD
University of Maryland School of Medicine
Philip Mease, MD
Michelle Petri, MD
Johns Hopkins University School of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”